Morecki S, Nagler A, Puyesky Y, Nabet C, Condiotti R, Pick M, Gan S, Slavin S
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Lymphokine Cytokine Res. 1993 Jun;12(3):159-65.
Efforts were directed to achieve an increased lymphokine-activated non-MHC-restricted killing (LAK) activity greater than that induced by rIL-2 alone. Human peripheral blood (PB) and bone marrow (BM)-derived mononuclear cells (MC) were exposed in vitro to multiple cytokine combinations, including rIL-6, rIL-7, rIFN-alpha and rIFN-gamma in the presence of either suboptimal or optimal doses of rIL-2. Our results have shown that BMMC are a potential source for induction of increased LAK activity upon exposure to multiple cytokine combinations, whereas PBMC could not be successfully stimulated under the same conditions. Fifty-five to 62% of BM-derived samples stimulated with high dose rIL-2 + rIL-7 or rIL-2 + rIL-7 + rIL-6 + rIFN-gamma exhibited a higher degree of cytotoxicity than BM samples stimulated with rIL-2 alone. Exposure of PB-derived large granular lymphocytes (LGL) to various cytokine combinations led to increased proliferation after stimulation with suboptimal dose of rIL-2 in the presence of rIL-6 and rIL-7. This increase was not observed in induction of cytotoxicity. We suggest that BMMC activated by multiple cytokine combinations could play an active role in improving antitumor response in vivo by contributing to the control of minimal residual tumor cell growth, particularly post-BM transplantation.
研究旨在提高淋巴因子激活的非主要组织相容性复合体(MHC)限制的杀伤(LAK)活性,使其高于单独使用重组白细胞介素-2(rIL-2)所诱导的活性。人外周血(PB)和骨髓(BM)来源的单个核细胞(MC)在体外暴露于多种细胞因子组合,包括rIL-6、rIL-7、rIFN-α和rIFN-γ,同时给予次优剂量或最佳剂量的rIL-2。我们的结果表明,骨髓单个核细胞(BMMC)在暴露于多种细胞因子组合后是诱导LAK活性增加的潜在来源,而在相同条件下外周血单个核细胞(PBMC)则不能被成功刺激。用高剂量rIL-2 + rIL-7或rIL-2 + rIL-7 + rIL-6 + rIFN-γ刺激的55%至62%的骨髓来源样本表现出比单独用rIL-2刺激的骨髓样本更高程度的细胞毒性。在rIL-6和rIL-7存在的情况下,用次优剂量的rIL-2刺激后,将外周血来源的大颗粒淋巴细胞(LGL)暴露于各种细胞因子组合会导致增殖增加。在细胞毒性诱导中未观察到这种增加。我们认为,由多种细胞因子组合激活的BMMC可能通过有助于控制微小残留肿瘤细胞生长,特别是在骨髓移植后,在改善体内抗肿瘤反应中发挥积极作用。